Concepedia

Michael Kauffman

MK

Statistics

Publications

121

Citations

12.5K

H-Index

55

Active since

1989

Affiliations

Karyopharm Therapeutics (United States)(Current)

Princess Margaret Cancer Centre

Hackensack University Medical Center

Dana-Farber Cancer Institute

Moffitt Cancer Center

Michael Kauffman is an author at Karyopharm Therapeutics (United States) specializing in medicine, oncology, and molecular oncology.

Publications per year

1989–2023

121

Publications

121

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

, , +10

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology · 2004 · 740 citations · Full text

, , +14

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

, , +15

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo et al. · The Lancet Haematology · 2020 · 337 citations · Full text

, , +11

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 324 citations · Full text

, , +16

1–5 of 121